Parallax Volatility Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-7,000
Closed -$3.39M 1842
2025
Q1
$3.39M Sell
7,000
-500
-7% -$233K 0.01% 723
2024
Q4
$3.02M Buy
7,500
+300
+4% +$139K 0.01% 1015
2024
Q3
$3.35M Hold
7,200
0.01% 955
2024
Q2
$3.37M Sell
7,200
-32,200
-82% -$14M 0.01% 849
2024
Q1
$16.5M Buy
39,400
+38,800
+6,467% +$16.4M 0.04% 366
2023
Q4
$244K Sell
600
-10,000
-94% -$3.69M ﹤0.01% 1742
2023
Q3
$3.69M Buy
10,600
+9,600
+960% +$3.36M 0.01% 880
2023
Q2
$352K Sell
1,000
-200
-17% -$67.4K ﹤0.01% 1763
2023
Q1
$378K Sell
1,200
-14,900
-93% -$4.47M ﹤0.01% 1816
2022
Q4
$4.65M Buy
16,100
+2,000
+14% +$610K 0.01% 1059
2022
Q3
$4.08M Sell
14,100
-72,300
-84% -$20.8M 0.01% 1108
2022
Q2
$24.3M Sell
86,400
-336,000
-80% -$89.9M 0.02% 430
2022
Q1
$110M Sell
422,400
-84,400
-17% -$20M 0.06% 120
2021
Q4
$111M Buy
506,800
+454,200
+863% +$88.3M 0.13% 104
2021
Q3
$9.54M Sell
52,600
-13,200
-20% -$2.58M 0.01% 661
2021
Q2
$13.3M Buy
65,800
+1,800
+3% +$377K 0.02% 455
2021
Q1
$13.8M Buy
64,000
+30,400
+90% +$6.68M 0.03% 335
2020
Q4
$7.94M Buy
33,600
+18,700
+126% +$4.29M 0.01% 797
2020
Q3
$4.05M Sell
14,900
-21,200
-59% -$5.85M ﹤0.01% 1414
2020
Q2
$10.5M Buy
36,100
+19,300
+115% +$5.23M 0.01% 765
2020
Q1
$4M Hold
16,800
0.01% 960
2019
Q4
$3.68M Buy
16,800
+11,300
+205% +$2.29M ﹤0.01% 1019
2019
Q3
$933K Sell
5,500
-7,500
-58% -$1.33M ﹤0.01% 1407
2019
Q2
$2.38M Buy
13,000
+9,700
+294% +$1.7M ﹤0.01% 981
2019
Q1
$607K Sell
3,300
-34,400
-91% -$6.35M ﹤0.01% 1459
2018
Q4
$6.25M Buy
+37,700
New +$6.53M 0.01% 659
2017
Q1
Sell
-25,000
Closed -$1.84M 4742
2016
Q4
$1.84M Hold
25,000
﹤0.01% 1002
2016
Q3
$2.18M Buy
+25,000
New +$2.36M ﹤0.01% 977
2015
Q4
Sell
-15,000
Closed -$1.56M 4011
2015
Q3
$1.56M Buy
+15,000
New +$1.93M ﹤0.01% 1124

Other funds holding VRTX

Parallax Volatility Advisers's VRTX Position: Q3 2025 in Review

Parallax Volatility Advisers sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 1,046 shares — an estimated $466K sold.

Parallax Volatility Advisers first reported a position in VRTX in Q2 2014 and held it in 29 quarters. The position peaked at $8.99M in Q1 2017. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Parallax Volatility Advisers reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Parallax Volatility Advisers sold 1,046 Vertex Pharmaceuticals shares in Q3 2025, an estimated $466K.
  • Parallax Volatility Advisers first reported a position in Vertex Pharmaceuticals in Q2 2014 and held it in 29 quarters.
  • Parallax Volatility Advisers's Vertex Pharmaceuticals position peaked at $8.99M in Q1 2017.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Parallax Volatility Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.